Study Summary
This study aims to evaluate the safety, efficacy and duration of response of CD19 Chimeric Antigen Receptor (CAR) redirected autologous T-cells in patients with high risk, relapsed CD19+ haematological malignancies.
Want to learn more about this trial?
Request More InfoInterventions
Anti-CD19-CARBIOLOGICAL
Cells extracted, followed by induction chemotherapy before CD19-CAR infusion (dose escalation.)
Study Locations
| Facility | City | State | Country |
|---|---|---|---|
| Beijing Cancer Hospital | Beijing | Beijing Municipality | China |
| The First Affiliated Hospital of Guangzhou Medical University | Guangzhou | Guangdong | China |
| Hebei Yanda Ludaopei Hospital | Sanhe | Hebei | China |
| First Affiliated Hospital of Henan University of Science and Technology | Luoyang | Henan | China |
| The First Affiliated Hospital of Zhengzhou University | Zhengzhou | Henan | China |
| Huai'An First People'S Hospital | Huaian | Jiangsu | China |
| Nanjing Drum Tower Hospital | Nanjing | Jiangsu | China |
| First Hospital of Jilin University | Changchun | Jilin | China |
| Shanxi Dayi Hospital | Taiyuan | Shanxi | China |
| Tianjin people's hospital | Tianjin | Tianjin Municipality | China |
| Hangzhou Cancer Hospital | Hangzhou | Zhejiang | China |
| Beijing DOING Biomedical Co., Ltd | Beijing | China |